Drug Profile
Pramipexole
Alternative Names: BI-Sifrol; Daquiran; Mirapex; Mirapex ER; Mirapex LA; Mirapexin; Pexola; Pramipexole extended-release - Boehringer Ingelheim; Sifrol; Sirfrol ER; SND 919; SND 919YLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Antidepressants; Antiparkinsonians; Benzothiazoles; Small molecules
- Mechanism of Action Dopamine D2 receptor agonists; Dopamine D3 receptor agonists; Dopamine D4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Parkinson's disease; Restless legs syndrome
- No development reported Myoclonus
- Discontinued Fibromyalgia; Gilles de la Tourette's syndrome; Schizophrenia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Myoclonus in USA (PO)
- 11 Jan 2012 Boehringer Ingelheim completes a phase III trial in Parkinson's disease in China (NCT01191944)
- 20 Jul 2011 Launched for Parkinson's disease in Japan (PO)